EGFR and neoplasm: Despite unfavorable conditions such as tumor shedding (ctDNA EGFRm‐positive), relatively advanced age (mean age, 68.5 years), and the presence of brain metastases (33%), the present trial showed ORR and PFS similar to those of previous trials where patients were recruited based on tumor EGFR genotyping.